Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40

Nat Rev Immunol. 2004 Jun;4(6):420-31. doi: 10.1038/nri1371.
No abstract available

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Autoimmune Diseases / drug therapy
  • CD28 Antigens / physiology
  • Drug Delivery Systems
  • Humans
  • Immune System Diseases / drug therapy*
  • Inflammation / drug therapy
  • Lymphocyte Activation
  • Membrane Glycoproteins / antagonists & inhibitors
  • Mice
  • Neoplasms / drug therapy
  • OX40 Ligand
  • Rats
  • Receptors, OX40
  • Receptors, Tumor Necrosis Factor / antagonists & inhibitors*
  • Receptors, Tumor Necrosis Factor / physiology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Tumor Necrosis Factors

Substances

  • Adjuvants, Immunologic
  • CD28 Antigens
  • Membrane Glycoproteins
  • OX40 Ligand
  • Receptors, OX40
  • Receptors, Tumor Necrosis Factor
  • TNFRSF4 protein, human
  • TNFSF4 protein, human
  • Tnfrsf4 protein, mouse
  • Tnfrsf4 protein, rat
  • Tnfsf4 protein, mouse
  • Tnfsf4 protein, rat
  • Tumor Necrosis Factors